Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0L1CX
|
||||
| Former ID |
DNC009922
|
||||
| Drug Name |
N-{4-[2-(3-Hydroxyphenyl)ethyl]phenyl}phthalimide
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C22H17NO3
|
||||
| Canonical SMILES |
C1=CC=C2C(=C1)C(=O)N(C2=O)C3=CC=C(C=C3)CCC4=CC(=CC=C4)O
|
||||
| InChI |
1S/C22H17NO3/c24-18-5-3-4-16(14-18)9-8-15-10-12-17(13-11-15)23-21(25)19-6-1-2-7-20(19)22(23)26/h1-7,10-14,24H,8-9H2
|
||||
| InChIKey |
TUMZBTITCWKZAT-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Oxysterols receptor LXR-alpha | Target Info | Inhibitor | [1] | |
| KEGG Pathway | PPAR signaling pathway | ||||
| Non-alcoholic fatty liver disease (NAFLD) | |||||
| Hepatitis C | |||||
| Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptor | ||||
| WikiPathways | Nuclear Receptors in Lipid Metabolism and Toxicity | ||||
| Nuclear Receptors Meta-Pathway | |||||
| PPAR Alpha Pathway | |||||
| Liver X Receptor Pathway | |||||
| Adipogenesis | |||||
| SREBF and miR33 in cholesterol and lipid homeostasis | |||||
| Nuclear Receptors | |||||
| References | |||||
| REF 1 | Bioorg Med Chem. 2009 Jul 15;17(14):5001-14. Epub 2009 Jun 2.Separation of alpha-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LXRalpha-selective antagonists. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.